Clinical Trial Update: Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pembrolizumab as first-line monotherapy and in combination for advanced gastric or gastroesophageal junction adenocarcinoma has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Gastric Adenocarcinoma | Phase 3 | Status: COMPLETED | Results posted: 2020-03-13